Thrombotic complications of erythropoiesis-stimulating agents.
about
The safety of pharmacologic options for the treatment of persons with hemophilia.Use of high-dose erythropoietin for repair after injury: A comparison of outcomes in heart and kidney.Chronic administration of small nonerythropoietic peptide sequence of erythropoietin effectively ameliorates the progression of postmyocardial infarction-dilated cardiomyopathy.Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyA small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage.Systemic treatment with erythropoietin protects the neurovascular unit in a rat model of retinal neurodegenerationPharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.Impact of Time-Varying Treatment Exposures on the Risk of Venous Thromboembolism in Multiple Myeloma.Management of anemia of inflammation in the elderlyClinical outcomes with use of erythropoiesis stimulating agents in patients with the HeartMate II left ventricular assist device.Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical MethodologiesIron in multiple myeloma.Cyclic Helix B Peptide in Preservation Solution and Autologous Blood Perfusate Ameliorates Ischemia-Reperfusion Injury in Isolated Porcine Kidneys.Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.The modern treatment of haemophilia: a narrative reviewHow do we treat life-threatening anemia in a Jehovah's Witness patient?The Protective Effects of Helix B Surface Peptide on Experimental Acute Liver Injury Induced by Carbon Tetrachloride.Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa).Drug-Induced Thrombophilic or Prothrombotic States.Indications for and complications of transfusion and the management of gynecologic malignancies.Reasons for moving toward a patient-centric paradigm of clinical transfusion medicine practice.Management of iron deficiency anemia in inflammatory bowel disease - a practical approach.Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction?Should ribavirin be used to treat hepatitis C in dialysis patients?Haemodilution is a mechanism of anaemia in patients with heart failure: reply.Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma
P2860
Q30249200-FA51C56A-A357-4C18-8700-6BFF5B1F0053Q30486662-D8D266F6-C5D4-4FCD-9F90-ABB480560777Q30539892-F8D569F0-E2AD-40D6-A67B-03457F4CBFBAQ34416394-2C7BFD47-C913-401D-8D03-81C4D54D223DQ34699514-D16A0A23-8154-4520-BD40-BB5A05C936F7Q35205276-E0C9894F-F40F-419A-A591-0460FC3C93D0Q35929084-B69D0739-34DE-4FEA-8115-E07ABE845473Q36229918-5B7FA770-878B-4FFE-9B5C-8B87077C4170Q36317698-DE57D849-49C5-427D-ABC6-6230745AFCA8Q36616210-0D838B15-E688-4A7F-B7D6-7003752DC29DQ37069353-9E5D4B59-A1BE-4300-9C31-AA483719134DQ37089777-43EB746B-C956-497B-A3BE-7A67A8374DBEQ37097716-F0F85E27-08B6-458F-AB01-692258F28C24Q37975484-E2A525AA-04E2-4AFD-B8F4-2CFCFB585F42Q38025882-51D332FA-33E2-494F-A1D4-FA925E2992F6Q38261467-51CB43E4-E42D-471B-BC35-0E3720799006Q38709407-BD81247D-3022-4711-A970-84AECCF69653Q38720560-BC343028-64A0-4A33-AF92-4274339714F7Q38853241-4091FDB5-8BEB-432A-A35A-CA6C2050763AQ39320771-728EDA81-B315-4820-80AB-5D2C3154BEFCQ39571357-35175D19-E85F-4497-BB44-48513D24BB14Q42406045-F89C5F86-1CB5-4040-BD0C-F7EF1659D643Q43046839-58F64609-F6D4-4D9F-8805-EDD04980175BQ45867154-6382491F-83B6-46E8-9F84-E628E748F54FQ47741344-77B64FDC-8A04-4E1F-A292-F739E465CD83Q57489994-3B468FEA-73EE-4EC9-B369-42CCBA0AB700
P2860
Thrombotic complications of erythropoiesis-stimulating agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Thrombotic complications of erythropoiesis-stimulating agents.
@en
Thrombotic complications of erythropoiesis-stimulating agents.
@nl
type
label
Thrombotic complications of erythropoiesis-stimulating agents.
@en
Thrombotic complications of erythropoiesis-stimulating agents.
@nl
prefLabel
Thrombotic complications of erythropoiesis-stimulating agents.
@en
Thrombotic complications of erythropoiesis-stimulating agents.
@nl
P50
P356
P1476
Thrombotic complications of erythropoiesis-stimulating agents.
@en
P304
P356
10.1055/S-0030-1255448
P577
2010-07-14T00:00:00Z